Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

China BioPharma Receives Approval from PRC Regulatory Agency.


ISELIN, N.J. -- Techedge, Inc. (OTCBB OTCBB

See OTC Bulletin Board (OTCBB).
:TEDG) is pleased to announce that China BioPharma Limited, the Company's wholly owned subsidiary Wholly Owned Subsidiary

A subsidiary whose parent company owns 100% of its common stock.

Notes:
In other words, the parent company owns the company outright and there are no minority owners.
, has received final approval from the PRC's (Peoples Republic of China) State Regulatory Agency state regulatory agency A state body responsible for establishing professional standards, and for certifying professionals or organizations through appropriate documentation  for the investment of China BioPharma, into Zhejiang Tianyuan Biotech Co., Ltd.

According to the approval, China BioPharma will have the direct ownership of 65% of Zhejiang Tianyuan Biotech Co., Ltd.

Dr. Shu, the CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of China BioPharma commented, "Receiving this approval is a great step for the company as it closes our venture together, and clears the way to begin the execution of our new business strategy and its action plan within the United States and China".

About China BioPharma Limited

China BioPharma is a fast growing developer, producer and distributor of bio-pharmaceutical products in China. Through its investment and ownership of leading Chinese bio-pharmaceutical companies, the Company's current products consist of human vaccines for influenza and epidemic hemorrhagic fever epidemic hemorrhagic fever
n.
An acute viral hemorrhagic fever characterized by headache, high fever, sweating, thirst, photophobia, coryza, cough, myalgia, arthralgia, and abdominal pain with nausea and vomiting.
 (HFV HFV High-frequency ventilation ) with high reputation and market shares among Chinese made vaccines. With a fast growing market, newly completed production facilities, and several other new vaccines in the pipeline, it is expected to have a steady and significant growth in the next few years. China BioPharma also plans to expand its market beyond China to other developing countries.

About Techedge Inc.

Techedge Inc. has recently repositioned itself to focus at opportunities in the fast growing bio-pharmaceutical sector in China. For more information, please visit its website at www.techedgeinc.net

FORWARD-LOOKING STATEMENT forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
 DISCLAIMER

Some of the statements made in this press release discuss future events and developments, including our future business strategy and our ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 31, 2006
Words:401
Previous Article:Lithium Technologies Welcomes New Vice President of Community Management; Joe Cothrel Brings Extensive Online Community Management Expertise to...
Next Article:Kofax Wins Best of Show at AIIM Conference for Document Scan Server.



Related Articles
Albright College and Process Recovery Corp to share laboratory facilities.
PortaCom Wireless Agrees to Acquire Asian American Telecom Corporation.
Great Wall Acquisition Corporation Announces That a Majority of the Shareholders of ChinaCast Communication Holdings Limited Have Irrevocably Agreed...
Sorenson Medical Receives Chinese FDA Approval to Provide Its ambIT PCA Ambulatory Infusion Pump for Pain Management throughout China.
Outsourcing U.S. security to China? The Bush administration is granting Hutchison Whampoa, a Hong Kong company with ties to China's military, the...
INC Research(R) Acquires Pharmaceutical Resource Corporation (PRC); Acquisition Gives INC Research Customers Expanded Late-Phase Trial Expertise.
AutoMart Wins Right to Service Government-Owned Cars in China.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles